✦ LIBER ✦

Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis

✍ Scribed by O'Hare, T.; Eide, C. A.; Agarwal, A.; Adrian, L. T.; Zabriskie, M. S.; MacKenzie, R. J.; LaTocha, D. H.; Johnson, K. J.; You, H.; Luo, J.; Riddle, S. M.; Marks, B. D.; Vogel, K. W.; Koop, D. R.; Apgar, J.; Tyner, J. W.; Deininger, M. W.; Druker, B. J.

Book ID: 124052158
Publisher: American Association for Cancer Research
Year: 2013
Tongue: English
Weight: 988 KB
Volume: 73
Category: Article
ISSN: 0008-5472
DOI: 10.1158/0008-5472.CAN-12-3904

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Importance of adherence to BCR-ABL tyros

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia

✍ de Almeida, Maria Helena; Fogliatto, Laura; Couto, Dulce 📂 Article 📅 2014 🏛 SciELO 🌐 English ⚖ 170 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

Selective induction of apoptosis in Phil

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

✍ Dan, Shingo; Naito, Mikihiko; Tsuruo, Takashi 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 272 KB

Frequency of ABL gene mutations in chron

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors

✍ Marcé, Silvia; Zamora, Lurdes; Cabezón, Marta; Xicoy, Blanca; Boqué, Concha; Fer 📂 Article 📅 2013 🏛 Elsevier Science 🌐 Spanish ⚖ 267 KB

Discontinuation of tyrosine kinase inhib

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia

✍ Breccia, Massimo; Alimena, Giuliana 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 309 KB